Financial Performance - Revenue reached $1813 million, a 102% increase compared to the previous year[20],[25] - Adjusted Gross Profit was $824 million, representing a 59% growth[20],[25] - Adjusted EBITDA stood at $107 million, remaining relatively flat compared to the prior year[20],[25] - Cash Flow from Operations increased significantly by 463% to $203 million[20],[25] - NGS revenue experienced substantial growth of 23% year-over-year[23] Margins and Profitability - Adjusted Gross Margin declined by 184 bps to 454%, primarily due to the Pathline acquisition[23],[25] - Adjusted EBITDA excluding Pathline grew by 13% compared to the previous year[23] Guidance and Outlook - The company revised its full-year 2025 revenue guidance to $720-$726 million, indicating a 9-10% year-over-year growth[24] - The company also updated its Adjusted EBITDA guidance for 2025 to $41-$44 million, reflecting a 3-10% year-over-year increase[24] Clinical Performance - Clinical volume reached 357 thousand units in Q2 2025[12] - Clinical revenue was $164 million in Q2 2025[14]